Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer

Modern Pathology

Volumn 16, Issue 3, 2003, Pages 198-205

  Ross, Jeffrey S ^a   Kaur, Prabhjot ^a   Sheehan, Christine E ^a   Fisher, Hugh A G ^a   Kaufman Jr , Ronald A ^a   Kallakury, Bhaskar V S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Immunohistochemistry; MMP; Prognosis; Prostate cancer; TIMP

Indexed keywords

GELATINASE A; MONOCLONAL ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CELL STRUCTURE; CONNECTIVE TISSUE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN DEGRADATION; TUMOR PROMOTION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0037339972     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000056984.62360.6C     Document Type: Article

References (63)

1. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
2. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-30.
3. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000;57:5-15.
4. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8.
5. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
6. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
7. Blavier L, Henriet P, Imren S, Declerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Ann N Y Acad Sci 1999;878:108-19.
8. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999;19:1589-92.
9. Baker AH, Ahonen M, Kahari V-M. Potential applications of tissue inhibitor metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol 2000;465:469-83.
10. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in esophageal cancer. J Pathol 1998;185:256-61.
11. Sier CFM, Kubben FJGM, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-7.
12. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
13. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62.
14. Bramhall SR, Neoptolemos JR, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347-55.
15. Kitamura H, Oosawa Y, Kawano N, Kameda Y, Hayashi H, Nakatani Y, et al. Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. Hum Pathol 1999;30:331-8.
16. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun H-J, Ringert R-H. Expression of metalloproteinase2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998;160:1914-8.
17. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase2. Gynecol Oncol 1996;62:89-99.
18. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 1996;26:303-9.
19. Ree AH, Florenes VA, Berg JP, Malandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastasis. Clin Cancer Res 1997;3:1623-8.
20. Fong KM, Kida Y, Zimmerman PV, Smith PJ. TIMP-1 an adverse prognosis in non-small cell cancer. Clin Cancer Res 1996;2:1369-72.
21. Lokeshwar BL. MMP inhibition in prostate cancer. Ann N Y Acad Sci 1999;878:271-89.
22. Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. Int J Cancer 2000;87:276-82.
23. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000;155:173-9.
24. Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998-1999;18:297-305.
25. Luo J, Lubaroff DM, Hendrix MJ. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999;59:3552-6.
26. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999;5:4105-10.
27. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000;42:18-25.
28. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996;8:69-75.
29. Stearns ME, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 1996;8:63-7.
30. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994;69:177-82.
31. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991;117:144-50.
32. Sang QA, Schwartz MA, Li H, Chung LW, Zhau HE. Targeting matrix metalloproteinases in human prostate cancer. Ann N Y Acad Sci 1999;878:538-40.
33. Hashimoto K, Kihira Y, Matuo Y, Usui T. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998;160:1872-6.
34. Lein M, Nowak L, Jung K, Laube C, Ulbricht N, Schnorr D, et al. Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue. Ann N Y Acad Sci 1999;878:544-6.
35. Jung K, Laube C, Lein M, Turk I, Lichtinghagen R, Rudolph B, et al. Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer. Int J Cancer 1998;78:392-3.
36. Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, Okada H, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998;79:96-101.
37. Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997;74:220-3.
38. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
39. Ohori M, Wheeler TM, Scardino PT. The new American Joint Committee on Cancer and International Union against Cancer. TNM classification of prostate cancer. Cancer 1994;74:104-14.
40. Kallakury BVS, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, et al. Decreased levels of CD44 protein and mRNA in prostate cancer. Correlation of tumor grade and ploidy. Cancer 1996;78:1461-9.
41. cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence and prostatic adenocarcinomas. J Clin Oncol 1998;16:1302-9.
42. Ross JS, Figge H, Bui HX, del Rosario AD, Jennings TA, Rifkin MD, et al. Prediction of pathologic stage and post-prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 1994;74:2811-8.
43. Ross JS, Sheehan CE, Ambros RA, Nazeer T, Jennings TA, Kaufman RP, et al. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol 1999;23:296-301.
44. Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2, and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998;77:2239-45.
45. Zucker S, Hymowitz M, Conner C, Zarribi HM, Hurewitz AN, Matrisian L, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212-27.
46. Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999;59:3313-6.
47. Boag AH, Young ID. Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma. Mod Pathol 1993;6:65-8.
48. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994;69:177-82.
49. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991;83:775-9.
50. Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T, Seiki M. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor metalloproteinase1 gene in nude mice. Cancer 1996;77:1676-80.
51. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenous (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996;73:972-8.
52. Alonso DF, Skilton G, DeLorenzo MS, Scursoni AM, Yoshiji H, Gomez DE. Histopathologic findings in a highly invasive mouse mammary carcinoma transfected with human tissue inhibitor of metalloproteinases-1. Oncol Rep 1998;5:1083-7.
53. Nemeth JA, Rafe A, Steiner M, Goolsby CL. TIMP-2 growth stimulatory activity: a concentration and cell-type specific response in the presence of insulin. Exp Cell Res 1996;224:110-5.
54. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, et al. High levels of tissue inhibitors metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996;56:1654-9.
55. Shofuda K, Moriyama K, Nishihashi A, Higashi S, Mizushima H, Yasumitsu H, et al. Role of tissue inhibitor of metalloproteinase-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem 1998;124:462-70.
56. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, VanWestrum SS, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of pro-gelatinase A - a kinetic study. J Biol Chem 1998;273:871-80.
57. Toth M, Bernardo MM, Gervasi DC, Soloway PG, Wang Z, Bigg HF, et al. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem 2000;275:41415-23.
58. Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via c-AMP-dependent mechanism. J Biol Chem 1995;270:13458-9.
59. Yamashita K, Suzuki M, Iwata H, Koike T, Hamaguchi M, Shinagawa A, et al. Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett 1996;396:103-7.
60. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor metalloproteinases-1. J Clin Invest 1998;102:2002-10.
61. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth promoting activity of tissue inhibitor metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:2373-9.
62. DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991;51:2151-7.
63. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995;6:967-74.